Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Michael L. Maitland, Matthew R. Levine, Mario E. Lacouture, Kristen E. Wroblewski, Christine H. Chung, Ilyssa O. Gordon, Livia Szeto, Gail Ratko, Keyoumars Soltani, Mark F. Kozloff, Philip C. Hoffman, Ravi Salgia, David P. Carbone, Theodore G. Karrison, Everett E. Vokes

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Candidate predictive biomarkers for epidermal growth factor receptor inhibitors (EGFRi), skin rash and serum proteomic assays, require further qualification to improve EGFRi therapy in non-small cell lung cancer (NSCLC). In a phase II trial that was closed to accrual because of changes in clinical practice we examined the relationships among candidate biomarkers, quantitative changes in tumor size, progression-free and overall survival.Methods: 55 patients with progressive NSCLC after platinum therapy were randomized to receive (Arm A) cetuximab, followed by pemetrexed at progression, or (Arm B) concurrent cetuximab and pemetrexed. All received cetuximab monotherapy for the first 14 days. Pre-treatment serum and weekly rash assessments by standard and EGFRi-induced rash (EIR) scales were collected.Results: 43 patients (20-Arm A, 23-Arm B) completed the 14-day run-in. Median survival was 9.1 months. Arm B had better median overall (Arm B = 10.3 [95% CI 7.5, 16.8]; Arm A = 3.5 [2.8, 11.7] months P = 0.046) and progression-free survival (Arm B = 2.3 [1.6, 3.1]; Arm A = 1.6 [0.9, 1.9] months P = 0.11). The EIR scale distributed ratings among 6 rather than 3 categories but ordinal scale rash severity did not predict outcomes. The serum proteomic classifier and absence of rash after 21 days of cetuximab did.Conclusions: Absence of rash after 21 days of cetuximab therapy and the serum proteomic classifier, but not ordinal rash severity, were associated with NSCLC outcomes. Although in a small study, these observations were consistent with results from larger retrospective analyses. Trial registration: Clinicaltrials.gov Identifier NCT00203931.

Original languageEnglish (US)
Article number5
JournalBMC Cancer
Volume14
Issue number1
DOIs
StatePublished - Jan 4 2014

Keywords

  • Cetuximab
  • EGFR
  • Lung Cancer
  • Pemetrexed
  • Proteomics
  • Rash

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Fingerprint

Dive into the research topics of 'Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this